Janux Therapeutics Business Summary

Janux Therapeutics, Inc. (JANX) is a clinical-stage biopharmaceutical company that generates revenue primarily through high-value strategic collaborations and exclusive worldwide licensing agreements with global pharmaceutical leaders, including Bristol Myers Squibb and Merck. The company’s business model is built upon three proprietary technology platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). These platforms utilize a precision-masking approach to engineer bispecific antibodies that remain inert in systemic circulation and are only activated by proteases within the tumor microenvironment, thereby mitigating the cytokine release syndrome (CRS) and off-tumor toxicities common in traditional immunotherapies. Janux operates within the oncology and autoimmune segments, positioning itself as a leader in the next-generation "masked" T-cell engager market. Its primary competitors include CytomX Therapeutics, Carisma Therapeutics, Agenus, and Denali Therapeutics; Janux distinguishes itself through its superior pharmacokinetic design and the clinical validation of its lead candidates, JANX007 and JANX008, which target PSMA and EGFR respectively. Janux was founded in 2017 by President and CEO David Campbell, Ph.D., a veteran drug developer with over 25 years of experience who previously served as CSO or CEO of Sitari, Afraxis, and RQx. The current leadership team includes Chief Technical Officer Charles M. Winter, who oversees manufacturing and process development, and Chief Scientific Officer Thomas DiRaimondo, Ph.D., who leads platform innovation. In January 2026, the company further strengthened its clinical operations by appointing William Go, M.D., Ph.D., as Chief Medical Officer; Dr. Go brings a distinguished pedigree from Kite Pharma, where he led the pivotal ZUMA-1 trial for Yescarta, and A2 Biotherapeutics. The company is backed by a blue-chip roster of institutional investors, including Avalon Ventures, RA Capital Management, OrbiMed, and Point72 Asset Management. Its Board of Directors is chaired by Ronald W. Barrett, Ph.D., and features prominent industry figures such as Eric Dobmeier (former CEO of Chinook Therapeutics) and Natasha Hernday (former CBO of Seagen).